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 Among blood donors in May 2020, te overall seroprevalence of anti-SARS-CoV-2 
antibodies was 1.4%  
 Non-citizens had higher prevalence compared to citizens (odds ratio 13.6, p = 0.001).  
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ABSTRACT 
BACKGROUND: Serologic testing provides better understanding of SARS-CoV-2 prevalence 
and its transmission. This study is the first investigation of the prevalence of antibodies to SARS-
CoV-2 among blood donors in Saudi Arabia. 
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OBJECTIVE: To estimate the seroprevalence of anti-SARS-CoV-2 antibodies among blood 
donors in Saudi Arabia during the early phase of the current pandemic.  
METHODS: Serology results and epidemiological data were analyzed for 837 adult blood donors, 
with no confirmed SARS-CoV-2 infection, in Saudi Arabia from 20 to 25 May 2020. 
Seroprevalence was determined using electrochemical immunoassay for detecting anti-SARS-
CoV-2 antibodies.   
RESULTS: The overall seroprevalence of anti-SARS-CoV-2 antibodies was 1.4% (12/837). Non-
citizens had higher prevalence compared to citizens (odds ratio 13.6, p = 0.001). Having a 
secondary education as the highest level of education was also significantly associated with high 
seroprevalence compared to higher education (odds ratio 6.8, p = 0.005).  The data showed that 
the highest seroprevalence was in Makkah (8.1%), Madinah (4.1% with an OR of 0.48 (95% CI: 
0.12-1.94), Jeddah (2.3%; OR 0.27; 95%CI: 0.31-2.25), and Qassim (2.9 %, OR: 0.34; 95%CI: 
0.04-2.89) and these were not statistically different from the seroprevalence in Makkah region. 
CONCLUSIONS: At the early stage of the pandemic in Saudi Arabia, the seroprevalence of 
antibodies to SARS-CoV-2 among blood donors was low but was higher among non-citizens 
These findings showed that non-citizens and the less educated may be less attentive to preventive 
measures. Monitoring seroprevalence trend over time require repeated sampling.  
  
INTRODUCTION 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus causing 
CoronaVirus Disease 19 (COVID-19) infection at a pandemic scale and with rapid spread and was 
first detected in Wuhan city, China in December 2019 (AlJishi and Al-Tawfiq, 2020; Drosten et 
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al., 2015).   COVID-19 has a wide clinical spectrum from an asymptomatic or mild infection in 
most cases to a severe acute respiratory syndrome (SARS)  (Al-Tawfiq, 2020).  
The first confirmed COVID-19 case in Saudi Arabia was reported on March 2nd, 2020 (Al-Tawfiq 
and Memish, 2020a; AlJishi et al., 2021); and by May 20th, 2020, the reported cases reached 62545 
nationally and more than 4.8 million cases globally (World Health Organization(WHO), 2020).   
The main diagnostic tests for the detection of SARS-CoV-2 infection relies on molecular 
diagnostic tests, namely reverse transcription polymerase chain reaction (RT-PCR) (Al-Tawfiq 
and Memish, 2020b; Gronvall et al., 2020).   The use of serologic tests is important to understand 
the extent and prevalence of COVID-19 infections (Al-Tawfiq and Memish, 2020b).   In addition, 
such tests are needed to determine the proportion of the population that has an immune response 
to SARS-CoV-2.  
The clinical presentation and epidemiology of COVID-19 infection in Saudi Arabia parallel those 
from around the globe (Al-Omari et al., 2020; Al Mutair et al., 2020).   To understand the extent 
of the disease in Saudi Arabia,  the Ministry of Health (MoH) and the Saudi Center for Disease 
Prevention and Control (SCDC) conducted a nationwide serologic testing early May 2020 to 
estimate the prevalence of antibodies to SARS-CoV-2 in multiple settings and population 
including social care homes, rehabilitation centers, healthcare workers (Al Mutair et al., 2020), 
and blood donors.  The advantage of utilizing blood banks for seroprevalence studies is that they 
usually have frequent number of donors that could facilitate serial cross-sectional studies at 
multiple times.  
This study is the first investigation of the seroprevalence of antibodies to SARS-CoV-2 among 
blood donors in Saudi Arabia. The objectives of the study were to help determine the 
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seroprevalence and to support the understanding of the epidemiological characteristics including 
factors associated with infection. 
METHODS 
This is a cross-sectional study of SARS-CoV-2 antibody in blood donors.  All blood donors 
irrespective of their sociodemographic characteristics who presented for blood donation at one of 
24 main blood banks in Saudi Arabia were included in the study.   Blood donors with a 
contraindication for blood donation, those with a past or current confirmed SARS-CoV-2 
infection, and those who declined to give informed consent to participate in the study were 
excluded. 
The participants were included in the study from 20 to 25 May 2020.  The current study was 
conducted at the time when the Kingdom of Saudi Arabia had 62,000-80,000 cases and just before 
the peak of cases in the country (Alserehi et al., 2020).  All participants signed informed consents, 
and completed the study questionnaire.  
Study Questionnaire  
Each participant was instructed to complete a written questionnaire which covers demographic 
(age; sex; citizenship status; education level), clinical data (current symptom and date of onset; 
health conditions; and smoking behavior), and exposure characteristics (contacted a confirmed or 
suspected SARS-CoV-2 case, attended a gathering, and/or visited a healthcare setting during the 
last 14 days; and SARS-CoV-2 RT-PCR testing). Location information of the blood bank site and 
the province were also collected.   
Serum Sample Collection 
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Before beginning blood donation, 4 ml of blood samples were collected in a serum collection tube 
from each participant by a trained blood bank staff. All collected serum samples were transported 
and stored for antibody testing at one of the designated ministry of health (MoH) regional 
laboratories in the cities of Jeddah or Dammam per the study protocol and manufacturer’s 
instructions. 
Serological Testing  
To detect anti-SARS-CoV-2 antibodies, an electrochemiluminescent immunoassay (ECLIA) was 
performed using the Elecsys® Anti-SARS-CoV-2 test from Roche Diagnostics International Ltd. 
(Rotkreuz, Switzerland) for the qualitative detection of antibodies (including IgG) to SARS-CoV-
2. The test is based on in-solution double-antigen sandwich format that can detect antibodies using 
a recombinant protein representing the nucleocapsid (N) protein of SARS-CoV-2 (Lau et al., 2020; 
Migchelsen and Duggan, 2020; Muench et al., 2020).  The test has 99.8% sensitivity (14 days after 
a PCR-confirmed infection) and 99.5% specificity (with limited cross-reactivity of 4/792 (0.5%) 
to the 4 human coronaviruses causing common cold) (Muench et al., 2020).  The result of a sample 
is given either as reactive (i.e., positive for anti-SARS-CoV-2 antibodies if the result’s cut-off 
index is ≥1.0) or non-reactive (i.e., negative for anti-SARS-CoV-2 antibodies if the result’s cut-
off index is <1.0)(Migchelsen and Duggan, 2020).  
Statistical Analysis: 
Descriptive analysis was used to summarize the data using range and mean ± standard deviation 
(SD), as appropriate for continuous variables and proportion (%) for categorical variables. 
Inferential analysis was performed using t-test and chi-squared test as appropriate to compare 
participants’ demographic, clinical, and exposure characteristics between seropositive and 
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seronegative participants. Logistic regression was then performed to establish the correlates of 
seroprevalence using odds ratio (OR) for the statistically significant characteristics.  STATA® 
(Stata/IC software version 15.1) from StataCorp LLC. (College Station, Texas, USA) was used for 
performing statistical analysis. A two tailed p-value (p) <0.05 was considered statistically 
significant and 95% confidence interval (CI) was used, as appropriate, to report the estimates. 
Ethical Considerations 
This study was approved by the MoH’s Central Institutional Review Board (log number: 20-107M) 
according to the International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH)’s Good Clinical Practice (GCP) guidelines. The study 
national registration number at the National Committee of BioEthics, King Abdulaziz City for 
Science and Technology, Saudi Arabia is H-01-R-009. 
RESULTS: 
In total, 837 participating blood donors, aged 17 to 70 years, were included in the study.  Anti-
SARS-CoV-2 antibodies were detected in 12 (1.4%) of all participants (Table 1).  Males 
constituted 96% of the study participants and all seropositive participants.  National citizens 
formed 72% of the study participants but only 17% of the seropositive participants.  
There was no significant difference for mean age or prevalence in the different age group of 
seropositive and seronegative participants (table 1).  Other characteristics that had no significant 
difference for seroprevalence included gender, having current symptom, having a health condition, 
being a smoker, previous exposure to SARS-CoV-2 and/or a high-risk event in the last 14 days, or 
had SARS-CoV-2 RT-PCR testing. By contrast, citizenship status, education level, and directorate 
of health affairs (a proxy measure for the home address of the blood donor) had significant 
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difference for the prevalence of anti-SARS-CoV-2 antibodies between the seropositive and 
seronegative participants with p-value <0.001, 0.005, and 0.002, respectively.  
In logistic regression analysis, non-citizen participants had higher odds ratio of being seropositive 
than citizens (OR 13.6, 95% CI 2.96-62.75, p = 0.001) (table 2). Education level was also 
significantly associated with seroprevalence with participants reporting secondary education as the 
highest level of educational had higher odds than those reporting higher education (OR 6.8, 95% 
CI 1.79-25.95, p = 0.005).   The data showed that the highest seroprevalence was in Makkah 
(8.1%), Madinah (4.1% with an OR of 0.48 (95% CI: 0.12-1.94), Jeddah (2.3%; OR 0.27; 95%CI: 
0.31-2.25), and Qassim (2.9%, OR: 0.34; 95%CI: 0.04-2.89) and these were not statistically 
different from the seroprevalence in Makkah Region (table 2). 
DISCUSSION 
This study was conducted as part of Saudi Arabia nationwide serosurvey estimating the prevalence 
of antibodies to SARS-CoV-2 in multiple population groups that started around May 20th, 2020. 
The study investigated the seroprevalence among blood donors with no previously confirmed 
infection and explored their epidemiological characteristics. 
The overall prevalence of antibodies to SARS-CoV-2 among the participants was 1.4% with 
substantial variation in the different cities.   The low prevalence of antibodies might not indicate a 
true low prevalence of past infection.  In a review article (Tirupathi et al., 2020b), it was noted that 
antibody response can decrease in one to three months after acute infection (Long et al., 2020; 
Robbiani et al., 2020) and that the level of antibodies, persistence and duration of antibodies may 
differ among different patients (Lee et al., 2020; To et al., 2020; Xu et al., 2020).  This overall 
seroprevalence rate is lower than the rate of 2.36% among healthcare workers in Saudi Arabia 
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(Alserehi et al., 2020).  For non-citizens, the probability of testing positive for anti-SARS-CoV-2 
antibodies was 13.6 times higher than for citizens.  The difference in seroprevalence among 
citizens and non-citizens is likely related to the fact that there was a difference in the initial number 
of cases in Saudi Arabia.  The initial cases were initially reported more among non-citizens due to 
sociodemographic characteristics.  A similar disparity in the positivity rate of acute COVID-19 
infection was noted among different race and ethnicities (Tirupathi et al., 2020a).  Racial and ethnic 
minority families may live in congested and overcrowded households and this may lead to 
increased likelihood of contracting SARS-CoV-2 (Tirupathi et al., 2020a).  The difference in 
serology among different regions and among non-citizens compared to citizens may shed light on 
priorities for vaccine.  However, there are multiple factors that are being considered for prioritizing 
the vaccine based on risk of exposure and risk of disease and its associated morbidity and mortality.  
Also, the probability was 6.8 times higher for participants having secondary education than for 
those having higher education. The study found no significant association between the location of 
the directorate of health affairs and seroprevalence and no significant difference in seropositivity 
for the other characteristics including age group and sex.  
The seroprevalence in this study, albeit conducted among blood donors who had no confirmed 
SARS-CoV-2 infection, was consistent with most findings from other studies of the prevalence of 
anti-SARS-CoV-2 antibodies among blood or plasma donors, or of stored samples, from January 
to June 2020. Notwithstanding the differences in study methods and SARS-CoV-2 transmission 
patterns between different areas, most of these studies found low levels of seroprevalence of 0% 
to 23% (Erikstrup et al., 2020; Gallian et al., 2020; Grzelak et al., 2020; Luiz Amorim Filho1, 
Célia Landmann Szwarcwald, Sheila de Oliveira Garcia Mateos, Antonio Carlos Monteiro Ponce 
de Leon, Roberto de Andrade Medronho, Valdiléa Gonçalves Veloso, Josiane Iole França Lopes, 
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Luis Cristovão de Moraes Sobrino Porto, Alexandre Ch, 2020; Ng et al., 2020; Percivalle et al., 
2020; Sughayer et al., 2020; Thompson et al., 2020; Valenti et al., 2020).  
For example, 0% seroprevalence was reported in Amman city, Jordan (Sughayer et al., 2020); 
0.1% in the San Francisco Bay Area, California, USA (Ng et al., 2020); 0.9% (IgG) in 3 federal 
states (North Rhine-Westphalia, Hesse, and Lower Saxony) in Germany (Fischer et al., 2020); 
1.9% in Denmark (Erikstrup et al., 2020); 2.7% in blood donors in the Netherlands (Slot et al., 
2020b); 2.7% in 4 departmental areas  in France (Gallian et al., 2020); 3.0% in in two blood banks 
in Clermont and Noyon cities, Oise, France (Fontanet et al., 2020); 3.2% in Scotland (Thompson 
et al., 2020); 4.0% in the State of Rio de Janeiro, Brazil (Luiz Amorim Filho1, Célia Landmann 
Szwarcwald, Sheila de Oliveira Garcia Mateos, Antonio Carlos Monteiro Ponce de Leon, Roberto 
de Andrade Medronho, Valdiléa Gonçalves Veloso, Josiane Iole França Lopes, Luis Cristovão de 
Moraes Sobrino Porto, Alexandre Ch, 2020); 7.1% in Milan metropolitan area, Lombardy, Italy 
(Percivalle et al., 2020; Valenti et al., 2020); and 8.5% (overall weighted adjusted) in England 
(Erikstrup et al., 2020; Gallian et al., 2020; Grzelak et al., 2020; Luiz Amorim Filho1, Célia 
Landmann Szwarcwald, Sheila de Oliveira Garcia Mateos, Antonio Carlos Monteiro Ponce de 
Leon, Roberto de Andrade Medronho, Valdiléa Gonçalves Veloso, Josiane Iole França Lopes, Luis 
Cristovão de Moraes Sobrino Porto, Alexandre Ch, 2020; Ng et al., 2020; Percivalle et al., 2020; 
Sughayer et al., 2020; Thompson et al., 2020; Valenti et al., 2020).  
One study reported 23.0% seroprevalence in the Lodi Red Zone (in Lombardy region) in Italy 
which was highly affected by the pandemic and under complete lockdown (Percivalle et al., 2020). 
In this study, Makkah’s directorate of health affairs, the health authority for the city of Makkah 
and its surrounding areas, had the highest proportion of seropositivity with 8.1% prevalence 
compared to the other participating directorates. The city of Makkah itself was also highly affected 
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and under complete lockdown and had curfew for a longer time than the other cities in the country 
(Algaissi et al., 2020; Alserehi et al., 2020; Obeid et al., 2020).  In addition, Madinah had 14.6% 
of the cases and had 4.1% positivity rate.  On the other hand, the Eastern Province had about 19% 
of the cases and Riyadh had 20.2% of the cases with no positivity among blood donors at that time.  
The current study found a prevalence of 4.1% in Madinah.  A recent study showed a prevalence 
of 19.3% and that study was Mid-May to Mid-July 2020.  Thus, the difference could be related to 
the difference in the timing of these two studies (Mahallawi and Al-Zalabani, 2020).  Thus, other 
factors may had played in the contribution to the differences in the serology among blood donors. 
In the current study, we found that seroprevalence among secondary education was higher than 
those with higher education (OR 6.8, 95% CI 1.79-25.95, p = 0.005).  Similarly, in a study from 
the State of Rio de Janeiro in Brazil, there was a significant association between lower educational 
level among blood donors and higher prevalence of antibodies to SARS-CoV-2 (Luiz Amorim 
Filho1, Célia Landmann Szwarcwald, Sheila de Oliveira Garcia Mateos, Antonio Carlos Monteiro 
Ponce de Leon, Roberto de Andrade Medronho, Valdiléa Gonçalves Veloso, Josiane Iole França 
Lopes, Luis Cristovão de Moraes Sobrino Porto, Alexandre Ch, 2020).  
We found no significant difference for mean age or prevalence in the different age group of 
seropositive and seronegative participants.  In a study from the Netherlands, a significant positivity 
rate was found among younger donors aged 18-30 years with a prevalence of 4.2% compared to 
about 2.7% in other age groups(Slot et al., 2020a).   In addition, a significant association was found 
across geographical areas (Erikstrup et al., 2020).  Samples collected at later periods during study 
conduction were significantly associated with an increase in seroprevalence in the studies from 
Brazil and Milan metropolitan area in Italy (Luiz Amorim Filho1, Célia Landmann Szwarcwald, 
Sheila de Oliveira Garcia Mateos, Antonio Carlos Monteiro Ponce de Leon, Roberto de Andrade 
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Medronho, Valdiléa Gonçalves Veloso, Josiane Iole França Lopes, Luis Cristovão de Moraes 
Sobrino Porto, Alexandre Ch, 2020; Valenti et al., 2020).         
Therefore, to monitor SARS-CoV-2 spread and seroprevalence trend over time, nationwide 
repeated cross-sectional study is needed to better determine how is the prevalence changing in 
different areas of the country, especially if reported cases do not reflect the true scale of the 
pandemic, and to ascertain the cumulative population immunity.  Such epidemiologic study was 
done in different countries.  For example, the seroprevalence was 4.8% in the first week, 8.5% in 
the second week, 10.9% in the third week, 6.6% in the fourth week, and 10.8% in the fifth week 
in Switzerland (Fontanet et al., 2020).  However, the interpretation of serology tests so far is 
problematic especially with the fact that antibodies may not last for a long time.  One study showed 
that antibody response remains stable for two months (Fontanet et al., 2020). 
In conclusion, in the early stage of the pandemic in Saudi Arabia, the seroprevalence of antibodies 
to SARS-CoV-2 among blood donors was low but was higher among non-citizens and in high 
prevalence areas.  Monitoring seroprevalence trend over time require repeated sampling and 
testing to characterize the prevalence of COVID-19.  With the introduction of vaccination, such 
serologic testing would need to be looked at carefully. 
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Table 1. Characteristics of participating blood donors and seroprevalence of anti-SARS-
CoV-2 antibodies according to characteristics, Saudi Arabia, 20-25 May 2020.  











837 825 12 1.4 - 
Age2 range (years) 17-70 17-70 25-50 - - 
Age2, mean (SD) 
(years) 
33.3 (8.3) 33.2 (8.3) 37.4 (8.4) - 0.081 
Age2 group (years) - - - - 0.723 
17-19 23 23 0 0.0 - 
20-29 256 253 3 1.2 - 
30-39 381 377 4 1.0 - 
40-49 135 131 4 3.0 - 
50-59 34 33 1 2.9 - 
60-69 2 2 0 0.0 - 
70+ 1 1 0 0.0 - 
Sex3  -  -  - - 0.484 
Male 796 784 12 1.5 - 
Female 32 32 0 0.0 - 
Citizenship status4  -  -  - - <0.00
1 
Citizen  605 603 2 0.3 - 
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Non-citizen 231 221 10 4.3 - 
Education level5  -  -  - - 0.005 
Higher education  540 537 3 0.6 - 
Secondary 
education 
218 210 8 3.7 - 
Lower education 75 74 1 1.3 - 
Directorate of health 
affairs6 
 -  -  - - 0.002 
Aseer 51 51 0 0.0 - 
Baha 31 31 0 0.0 - 
Bisha 31 31 0 0.0 - 
Eastern Region  53 53 0 0.0 - 
Hafr Al Batin 31 31 0 0.0 - 
Hail 2 2 0 0.0 - 
Hasa  43 43 0 0.0 - 
Jazan 42 42 0 0.0 - 
Jeddah  43 42 1 2.3 - 
Madinah 73 70 3 4.1 - 
Makkah 86 79 7 8.1 - 
Najran 43 43 0 0.0 - 
Northern 
Borders  
23 23 0 0.0 - 
Qassim 34 33 1 2.9 - 
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Qunfudhah 23 23 0 0.0 - 
Qurayyat 22 22 0 0.0 - 
Riyadh 116 116 0 0.0 - 
Tabouk 29 29 0 0.0 - 
Taif 61 61 0 0.0 - 
Current symptom7  -  -  - - 0.574 
No 808 796 12 1.5 - 
Yes 21 21 0 0.0 - 
Health condition8  -  -  - - 0.673 
No 819 807 12 1.5 - 
Yes 12 12 0 0.0 - 
Smoker9   -  -  - - 0.067 
No 547 536 11 2.0 - 




19 case, attended 
gathering, and/or 
visited healthcare 
setting during last 14 
days) 
 -  -  - - 0.943 
No 691 681 10 1.5 - 
23 
 
Yes 146 144 2 1.4 - 
SARS-CoV-2 RT-
PCR testing10 
- - - - 0.231 
No 747 735 12 1.6 - 
Yes 88 88 0 0.0 - 
Abbreviations: COVID-19 = coronavirus disease 2019; ND = no data; p = p-value; RT-
PCR = reverse transcription polymerase chain reaction; SARS-CoV-2 = severe acute 
respiratory syndrome coronavirus 2; SD = standard deviation. 
1 5% significance level. Difference in mean age of seropositive and seronegative participants was 
tested using t-test. Differences in proportion of all other characteristics were tested using chi-
squared test especially Pearson’s chi-squared test.  
2 Age was unknown for 5 seronegative participants who were excluded from the analysis. 
3 Sex was unknown for 9 seronegative participants who were excluded from the analysis.  
4 Citizenship status was unknown for 1 seronegative participant who was excluded from the 
analysis.  
5 Education level was unknown for 4 seronegative participants who were excluded from the 
analysis.  
6 Serology samples were missing for Jouf’s directorate of health affairs in which they were 
excluded from the study.  
7 Current symptoms were unknown for 8 seronegative participants who were excluded from the 
analysis. The list of symptoms in the study questionnaire included cough, fever (>38.0˚ 
Celsius) or feeling feverish, headache, joint pain, nasal drip, nausea and/or vomiting, and sore 
throat. Bone pain was reported by 1 participant as other symptoms.  
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8 Health conditions were unknown for 6 seronegative participants who were excluded from the 
analysis. The list of health conditions in the study questionnaire included cardiac disease, 
chronic lung disease, diabetes, high blood pressure, and obesity. Asthma was reported by 1 
participant as other health conditions. 
9 Smoking behavior was unknown for 21 seronegative participants who were excluded from the 
analysis.  
10 Blood donors with confirmed SARS-CoV-2 infection were excluded from participation in the 
study. History of SARS-CoV-2 RT-PCR testing was unknown for 2 seronegative participants 









Table 2. Association of participating blood donors’ characteristics with the seroprevalence of anti-SARS-CoV-2 antibodies, 
Saudi Arabia, 20-25 May 2020. 




OR 95% CI p1 
Citizenship status  
Citizen 605 0.3 1.00 Ref. - 




540 0.3 1.00 Ref. - 
Secondary 
education 
218 4.3 6.81 1.79-25.95 0.005 
Lower education 75 1.3 2.41 0.24-23.55 0.447 
Directorate of health 
affairs 
Makkah 86 8.1 1.00 Ref. - 
Madinah 73 4.1 0.48 0.12-1.94 0.306 
Jeddah 43 2.3 0.27 0.31-2.25 0.226 
Qassim 34 2.9 0.34 0.04-2.89 0.324 
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Abbreviations: CI = confidence interval; OR = odds ratio; p = p-value; Ref. = reference; SARS-CoV-2 = severe acute respiratory 
syndrome coronavirus 2. 
1 5% significance level. Differences are relative to the variable listed first as a reference in each characteristic. 
